Apremilast & Guselkumab

Anti-IL-23 Guselkumab Beats Adalimumab in Severe Psoriasis

Management of moderate to severe plaque psoriasis has advanced significantly with FDA approved therapies capable of targeting TNF alpha, IL-17 and IL-12/23.

Sited just upstream from IL17 and IL22 in the Th17 pathway, Guselkumab holds hope for efficacy in the treatment of Spondyloarthritis, Psoriatic Arthritis and possibly the Inflammatory Bowel Diseases too.  Inhibition of IL22 downstream may reduce new bone formation and ankylosis in Ankylosing Spondylitis.

Apremilast Demonstrates Long-term Safety in Moderate-to-Severe Psoriasis and/or Psoriatic Arthritis

By Jenny Powers…

Its lesser potency and efficacy compared to the biologic agents like the anti-TNFs, anti-IL12/23 and anti-IL17 is “compensated” by it being an oral agent with excellent safety profile.  It fills the niche for needle-phobic patients with milder psoriatic disease.